Bhagiradha Chemicals & Industries Ltd
Bhagiradha Chemicals & Industries is an Agro Chemical Company in India involved in the manufacturing of insecticides, fungicides, herbicides etc. It was Promoted by late Sri S. Koteswara Rao, a former scientist of Indian Institute of Chemical Technology, Hyderabad in the year 1993.[1][2]
- Market Cap ₹ 4,076 Cr.
- Current Price ₹ 328
- High / Low ₹ 448 / 117
- Stock P/E 151
- Book Value ₹ 51.0
- Dividend Yield 0.03 %
- ROCE 9.69 %
- ROE 6.27 %
- Face Value ₹ 1.00
Pros
Cons
- Promoter holding has decreased over last quarter: -3.25%
- The company has delivered a poor sales growth of 1.16% over past five years.
- Promoter holding is low: 20.3%
- Company has a low return on equity of 13.7% over last 3 years.
- Dividend payout has been low at 7.02% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
146 | 174 | 220 | 152 | 203 | 183 | 384 | 246 | 318 | 436 | 502 | 407 | 396 | |
136 | 164 | 209 | 148 | 191 | 172 | 343 | 229 | 271 | 367 | 424 | 364 | 352 | |
Operating Profit | 10 | 11 | 11 | 4 | 11 | 12 | 41 | 17 | 47 | 68 | 78 | 43 | 44 |
OPM % | 7% | 6% | 5% | 3% | 6% | 6% | 11% | 7% | 15% | 16% | 16% | 11% | 11% |
0 | 1 | 1 | 1 | 2 | -8 | 1 | 4 | 2 | 1 | 2 | 5 | 13 | |
Interest | 4 | 4 | 6 | 7 | 7 | 7 | 8 | 5 | 8 | 9 | 5 | 8 | 7 |
Depreciation | 4 | 5 | 3 | 4 | 4 | 3 | 5 | 7 | 8 | 9 | 10 | 11 | 11 |
Profit before tax | 3 | 2 | 3 | -5 | 3 | -6 | 29 | 9 | 32 | 51 | 65 | 29 | 38 |
Tax % | 32% | 10% | 17% | -39% | 61% | -77% | 37% | 27% | 27% | 30% | 29% | 30% | |
2 | 2 | 3 | -3 | 1 | -1 | 18 | 7 | 23 | 36 | 46 | 20 | 27 | |
EPS in Rs | 0.32 | 0.31 | 0.40 | -0.51 | 0.16 | -0.14 | 1.78 | 0.63 | 2.28 | 3.50 | 4.46 | 1.95 | 2.34 |
Dividend Payout % | 0% | 26% | 20% | 0% | 0% | 0% | 9% | 0% | 0% | 7% | 9% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 1% |
3 Years: | 9% |
TTM: | -16% |
Compounded Profit Growth | |
---|---|
10 Years: | 26% |
5 Years: | 2% |
3 Years: | -4% |
TTM: | -11% |
Stock Price CAGR | |
---|---|
10 Years: | 50% |
5 Years: | 56% |
3 Years: | 66% |
1 Year: | 117% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 13% |
3 Years: | 14% |
Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 5 | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 12 |
Reserves | 41 | 43 | 44 | 41 | 46 | 94 | 120 | 124 | 148 | 182 | 304 | 322 | 622 |
39 | 53 | 71 | 62 | 64 | 61 | 47 | 43 | 62 | 81 | 50 | 61 | 85 | |
39 | 41 | 75 | 71 | 91 | 80 | 98 | 50 | 55 | 71 | 82 | 174 | 108 | |
Total Liabilities | 124 | 142 | 195 | 179 | 206 | 243 | 274 | 225 | 273 | 342 | 446 | 568 | 827 |
35 | 48 | 52 | 66 | 69 | 77 | 106 | 138 | 145 | 149 | 164 | 176 | 180 | |
CWIP | 12 | 9 | 16 | 0 | 0 | 0 | 4 | 4 | 1 | 3 | 6 | 5 | 30 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 9 | 42 | 80 | 147 |
77 | 85 | 127 | 113 | 138 | 166 | 164 | 83 | 119 | 181 | 234 | 306 | 470 | |
Total Assets | 124 | 142 | 195 | 179 | 206 | 243 | 274 | 225 | 273 | 342 | 446 | 568 | 827 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | 3 | 1 | 18 | 8 | -27 | 49 | 48 | 4 | 7 | 13 | 39 | |
-17 | -14 | -15 | -0 | -6 | -13 | -38 | -39 | -21 | -17 | -59 | -128 | |
8 | 10 | 13 | -17 | -2 | 43 | -12 | -9 | 15 | 12 | 46 | 88 | |
Net Cash Flow | -0 | -2 | -1 | 1 | -0 | 3 | -1 | 0 | -2 | 2 | -0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 89 | 71 | 82 | 67 | 31 | 71 | 80 | 17 | 68 | 81 | 94 | 95 |
Inventory Days | 103 | 99 | 139 | 256 | 282 | 281 | 77 | 137 | 97 | 91 | 108 | 166 |
Days Payable | 113 | 104 | 143 | 216 | 205 | 191 | 110 | 59 | 89 | 73 | 69 | 95 |
Cash Conversion Cycle | 78 | 66 | 78 | 106 | 108 | 161 | 47 | 95 | 76 | 99 | 132 | 167 |
Working Capital Days | 85 | 85 | 82 | 80 | 66 | 133 | 50 | 35 | 71 | 91 | 115 | 160 |
ROCE % | 8% | 7% | 8% | 0% | 8% | 7% | 22% | 7% | 20% | 25% | 22% | 10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14 Nov - Monitoring Agency Report for convertible warrants issued.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
13 Nov - Investor Presentation for the Quarter and Half year ended September 30, 2024.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Submission of copies of Newspaper Publication of the Un-Audited Financial Results for the quarter ended September 30, 2024
-
Statement Of Deviation (S) Or Variation(S) For The Quarter Ended September 30, 2024
12 Nov - Statement confirming no deviation in fund utilization.
-
Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024
12 Nov - Board approved un-audited financial results for Q2 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2024TranscriptNotesPPT
Product Portfolio
The company's product portfolio includes a wide range of insecticides, fungicides, herbicides, and speciality intermediaries -
a. Insecticides: Chlorpyrifos, Diafenthiuron, Fipronil, Buprofezin, etc.
b. Fungicides: Azoxystrobin
c. Herbicides: Imazethapyr, Clodinafop-propargyl, Cloquintocet-mexyl
d. Specialty-intermediaries: R-HPPA, 2,6-Dichloroaniline, etc [1]